Congress Wealth Management LLC DE Sells 2,595 Shares of Pfizer Inc. (NYSE:PFE)
General news

Congress Wealth Management LLC DE Sells 2,595 Shares of Pfizer Inc. (NYSE:PFE)


Congress Wealth Management LLC DE decreased its stake in shares of Pfizer Inc. (NYSE:PFEFree Report) by 6.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 40,447 shares of the biopharmaceutical company’s stock after selling 2,595 shares during the period. Congress Wealth Management LLC DE’s holdings in Pfizer were worth $1,342,000 at the end of the most recent quarter.

Several other large investors also recently made changes to their positions in the stock. Front Street Capital Management Inc. grew its position in Pfizer by 4.3% in the first quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock valued at $268,000 after purchasing an additional 215 shares in the last quarter. Capital Planning Advisors LLC grew its position in Pfizer by 1.8% in the second quarter. Capital Planning Advisors LLC now owns 16,091 shares of the biopharmaceutical company’s stock valued at $590,000 after purchasing an additional 281 shares in the last quarter. Graves Light Lenhart Wealth Inc. grew its position in shares of Pfizer by 1.4% in the 2nd quarter. Graves Light Lenhart Wealth Inc. now owns 19,863 shares of the biopharmaceutical company’s stock valued at $729,000 after acquiring an additional 281 shares during the period. V Wealth Advisors LLC grew its position in shares of Pfizer by 0.9% in the 2nd quarter. V Wealth Advisors LLC now owns 31,001 shares of the biopharmaceutical company’s stock valued at $1,137,000 after acquiring an additional 282 shares during the period. Finally, Infrastructure Capital Advisors LLC grew its position in shares of Pfizer by 5.2% in the 2nd quarter. Infrastructure Capital Advisors LLC now owns 5,751 shares of the biopharmaceutical company’s stock valued at $211,000 after acquiring an additional 284 shares during the period. Institutional investors own 68.05% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on PFE shares. Truist Financial decreased their price objective on shares of Pfizer from $42.00 to $36.00 and set a “buy” rating for the company in a research report on Thursday, December 14th. Wells Fargo & Company dropped their target price on shares of Pfizer from $39.00 to $35.00 and set an “equal weight” rating for the company in a research report on Monday, October 16th. TheStreet cut shares of Pfizer from a “b-” rating to a “c+” rating in a research report on Monday, September 25th. Barclays decreased their price target on shares of Pfizer from $34.00 to $28.00 and set an “equal weight” rating on the stock in a report on Thursday, December 14th. Finally, JPMorgan Chase & Co. decreased their price target on shares of Pfizer from $36.00 to $34.00 and set a “neutral” rating on the stock in a report on Monday, October 16th. Thirteen investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $38.22.

Get Our Latest Stock Report on Pfizer

Pfizer Stock Performance

PFE opened at $28.70 on Monday. The company has a current ratio of 2.38, a quick ratio of 2.05 and a debt-to-equity ratio of 0.63. The company’s fifty day moving average price is $29.14 and its two-hundred day moving average price is $32.59. Pfizer Inc. has a 1-year low of $25.76 and a 1-year high of $48.16. The company has a market cap of $162.05 billion, a price-to-earnings ratio of 15.68, a PEG ratio of 1.82 and a beta of 0.60.

Pfizer (NYSE:PFEGet Free Report) last released its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, topping the consensus estimate of ($0.32) by $0.15. Pfizer had a net margin of 15.30% and a return on equity of 16.72%. The firm had revenue of $13.23 billion for the quarter, compared to the consensus estimate of $13.77 billion. On average, analysts expect that Pfizer Inc. will post 1.54 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 1st. Stockholders of record on Friday, January 26th will be paid a $0.42 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.41. The ex-dividend date is Thursday, January 25th. This represents a $1.68 annualized dividend and a dividend yield of 5.85%. Pfizer’s dividend payout ratio is presently 89.62%.

Insider Transactions at Pfizer

In other news, Director Scott Gottlieb bought 3,000 shares of Pfizer stock in a transaction dated Friday, December 15th. The stock was purchased at an average price of $26.47 per share, for a total transaction of $79,410.00. Following the purchase, the director now directly owns 9,000 shares in the company, valued at approximately $238,230. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.05% of the company’s stock.

Pfizer Profile

(Free Report)

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Read More

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)



Receive News & Ratings for Pfizer Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Pfizer and related companies with MarketBeat.com’s FREE daily email newsletter.

Comments Off on Congress Wealth Management LLC DE Sells 2,595 Shares of Pfizer Inc. (NYSE:PFE)